Probiont
Develops organ-on-a-chip solutions to test cancer immunotherapy efficacy for personalized treatment assessment
Highlights
- New on EvolcAdded 2026-10-31
About Probiont
Probiont develops personalized cancer immunotherapy efficacy testing solutions using organ-on-a-chip technology. Its technology is designed to replicate patient-specific physiology and screen cancer drugs before treatment decisions.
The company is based at Terkko Health Hub in Helsinki, Finland. Probiont Oy was founded in 2021.
Product: Organ-on-a-chip technology for personalized cancer immunotherapy efficacy testing and drug screening.
Jobs at Probiont
No open positions listed right now.
More biotech & pharma companies
Puro Analytics
EDNA biodiversity monitoring for organisations: species detection, fish and forest surveys, lab analysis and reportsYoung companyNew on EvolcRappta Therapeutics
Develops first-in-class anti-cancer molecular glues that reactivate the tumor suppressor PP2A, for oncology drug developmentNew on EvolcReagena
Diagnostic tests and laboratory reagents for clinical, biotechnology, pharmaceutical and research organizationsNew on EvolcReBio Technologies
Develops targeted, locally delivered drug conjugates for ocular cancers, starting with uveal melanomaNew on EvolcReplicon Health
Develops oral drug candidate RH013001 for aging-related degenerative diseases and seeks pharma partners to bring it to marketNew on EvolcRNatives
Develops RNA-based gene-regulating therapies for serious diseases, with research and offices in Kuopio, FinlandNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- LiteSpeed
- WordPress
- jQuery